ARTICLE | Clinical News

Pulmaquin liposomal ciprofloxacin: Phase III started

May 5, 2014 7:00 AM UTC

Aradigm began the international Phase III ORBIT-3 trial of Pulmaquin in 255 patients. In the double-blind portion, patients will receive Pulmaquin or placebo once daily for a 28-day cycle, followed by 28 days off treatment, for up to 6 cycles. The trial also has a 28-day, open-label extension. This half, Aradigm will start the identical ORBIT-4 trial in the indication. ...